Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
mRNA-3927 Extension Study in Propionic Acidemia
NCT05130437Phase 2Recruiting
- Sponsor
- Moderna Inc
- Start
- Nov 2021
- Primary completion
- Dec 2029
- Modality
- Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 8
01
Overview
A Phase 2 trial of mRNA-3927 in propionic acidemia (PA), sponsored by Moderna Inc. Started Nov 2021; status: recruiting.
02
Drugs
mRNA-3927
03
Conditions
propionic acidemia (PA)
Beyond the preview
Go deeper on NCT05130437.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05130437.